Incyte’s Opzelura Outlook Trails Estimates, Intensifying Jakafi Patent Concerns
Incyte issued a conservative sales projection for its topical drug Opzelura for 2026 that fell short of Wall Street forecasts, deepening investor concern about the company’s ability to replace revenue as its top product Jakafi approaches patent expiration. The company reported stronger-than-expected overall revenue for the quarter but missed on adj…